Iranian Red Crescent Medical Journal

Published by: Kowsar

Hormone Replacement Therapy and Postmenopausal Cardiovascular Events: A Meta-Analysis

Shirvan Salaminia 1 , Yousof Mohsenzadeh 2 , Morteza Motedayen 3 , * , Fatemeh Sayehmiri 4 and Majid Dousti 5
Authors Information
1 Department of Cardiac Surgery, Yasuj University of Medical Sciences, Yasuj, Iran
2 Department of Cardiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3 Department of Cardiology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
4 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Parasitology, Faculty of Medicine, Shiraz University of Medical Sciences, Fars, Iran
Article information
  • Iranian Red Crescent Medical Journal: 21 (2); e82298
  • Published Online: February 27, 2019
  • Article Type: Systematic Review
  • Received: July 17, 2018
  • Revised: September 28, 2018
  • Accepted: January 29, 2019
  • DOI: 10.5812/ircmj.82298

To Cite: Salaminia S , Mohsenzadeh Y , Motedayen M , Sayehmiri F, Dousti M . Hormone Replacement Therapy and Postmenopausal Cardiovascular Events: A Meta-Analysis, Iran Red Crescent Med J. Online ahead of Print ; 21(2):e82298. doi: 10.5812/ircmj.82298.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Introduction
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Rajaeefard A, Mohamadbeygi A, Mohammadsalehi N. [The estimated mean age at menopause in Iranian women: A study Mtanalyz]. Komesh. 2011;13(1). Persian.
  • 2. Nanbakhsh F, Mohadesi H, Mirabi A, Hagishafieiha M, Bromand F, Bahadori F. [Elderly health effects of education on knowledge, attitude and practice of older women]. J Fac Tehran Univ Med Sci (Payavard Salamat). 2011;5(1):47-57. Persian.
  • 3. Rogerio A. Treatment of the postmenopausal woman. 2nd ed. 1999. p. 157-8. 581.
  • 4. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75(6):1102-9. doi: 10.1161/01.CIR.75.6.1102. [PubMed: 3568321].
  • 5. Whayne TF Jr, Mukherjee D. Women, the menopause, hormone replacement therapy and coronary heart disease. Curr Opin Cardiol. 2015;30(4):432-8. doi: 10.1097/HCO.0000000000000157. [PubMed: 25695898].
  • 6. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: What shall we do now? Lancet. 2005;366(9483):409-21. doi: 10.1016/S0140-6736(05)66519-1. [PubMed: 16054942].
  • 7. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study. Bone. 2004;34(4):728-35. doi: 10.1016/j.bone.2003.12.021. [PubMed: 15050905].
  • 8. [No authors listed]. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-59. doi: 10.1016/S0140-6736(97)08233-0. [PubMed: 10213546].
  • 9. Gibson CL, Gray LJ, Murphy SP, Bath PM. Estrogens and experimental ischemic stroke: A systematic review. J Cereb Blood Flow Metab. 2006;26(9):1103-13. doi: 10.1038/sj.jcbfm.9600270. [PubMed: 16437060].
  • 10. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain. 2008;131(Pt 2):318-28. doi: 10.1093/brain/awm183. [PubMed: 17715141].
  • 11. Suzuki S, Brown CM, Wise PM. Mechanisms of neuroprotection by estrogen. Endocrine. 2006;29(2):209-15. doi: 10.1385/ENDO:29:2:209. [PubMed: 16785597].
  • 12. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47-63. doi: 10.1016/0091-7435(91)90006-P. [PubMed: 1826173].
  • 13. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016-37. doi: 10.7326/0003-4819-117-12-1016. [PubMed: 1443971].
  • 14. Kaplan NM, Burton DR. Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure. 2016. Available from:
  • 15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. doi: 10.1001/jama.280.7.605. [PubMed: 9718051].
  • 16. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343(8):522-9. doi: 10.1056/NEJM200008243430801. [PubMed: 10954759].
  • 17. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA. 2003;289(20):2673-84. doi: 10.1001/jama.289.20.2673. [PubMed: 12771114].
  • 18. Yang D, Li J, Yuan Z, Liu X. Effect of hormone replacement therapy on cardiovascular outcomes: A meta-analysis of randomized controlled trials. PLoS One. 2013;8(5). e62329. doi: 10.1371/journal.pone.0062329. [PubMed: 23667467]. [PubMed Central: PMC3648543].
  • 19. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103(5):638-42. doi: 10.1161/01.CIR.103.5.638. [PubMed: 11156873].
  • 20. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49-57. doi: 10.1001/jama.288.1.49. [PubMed: 12090862].
  • 21. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA. 2002;288(19):2432-40. doi: 10.1001/jama.288.19.2432. [PubMed: 12435256].
  • 22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi: 10.1001/jama.288.3.321. [PubMed: 12117397].
  • 23. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523-34. doi: 10.1056/NEJMoa030808. [PubMed: 12904517].
  • 24. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243-9. doi: 10.1056/NEJMoa010534. [PubMed: 11680444].
  • 25. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12. doi: 10.1001/jama.291.14.1701. [PubMed: 15082697].
  • 26. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. 2006;55(2):162-73. doi: 10.1016/j.maturitas.2006.01.012. [PubMed: 16504428].
  • 27. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): A randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. doi: 10.1136/bmj.39266.425069.AD. [PubMed: 17626056]. [PubMed Central: PMC1939792].
  • 28. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med. 2014;161(4):249-60. doi: 10.7326/M14-0353. [PubMed: 25069991].
  • 29. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-68. doi: 10.1001/jama.2013.278040. [PubMed: 24084921]. [PubMed Central: PMC3963523].
  • 30. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-31. doi: 10.1056/NEJMoa1505241. [PubMed: 27028912]. [PubMed Central: PMC4921205].
  • 31. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ. 2012;345. e6409. doi: 10.1136/bmj.e6409. [PubMed: 23048011].
  • 32. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. doi: 10.1001/jama.297.13.1465. [PubMed: 17405972].
  • 33. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-602. doi: 10.1056/NEJMoa071513. [PubMed: 17582069].
  • 34. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-45. doi: 10.1001/jama.299.9.1036. [PubMed: 18319414].
  • 35. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA. 2011;305(13):1305-14. doi: 10.1001/jama.2011.382. [PubMed: 21467283]. [PubMed Central: PMC3656722].
  • 36. Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the Women's Health Initiative Observational Study. Menopause. 2014;21(3):260-6. doi: 10.1097/GME.0b013e31829a64f9. [PubMed: 24045672]. [PubMed Central: PMC3872264].
  • 37. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ. 2010;340:c2519. doi: 10.1136/bmj.c2519. [PubMed: 20525678].
  • 38. Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-79. doi: 10.1097/EDE.0b013e3181875e61. [PubMed: 18854702]. [PubMed Central: PMC3731075].
  • 39. Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernan MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: Does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152(4):211-7. doi: 10.7326/0003-4819-152-4-201002160-00005. [PubMed: 20157135]. [PubMed Central: PMC2936769].
  • 40. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16(4):639-43. doi: 10.1097/gme.0b013e31819c11e4. [PubMed: 19325499]. [PubMed Central: PMC2856618].
  • 41. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: Role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 2008;168(8):861-6. doi: 10.1001/archinte.168.8.861. [PubMed: 18443262]. [PubMed Central: PMC4001717].
  • 42. Tannen RL, Weiner MG, Xie D, Barnhart K. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod. 2007;22(6):1769-77. doi: 10.1093/humrep/dem031. [PubMed: 17347166].
  • 43. Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016;65(5):794-803. doi: 10.1016/j.metabol.2016.01.004. [PubMed: 27085786]. [PubMed Central: PMC4834454].
  • 44. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: A national register study. Eur Heart J. 2008;29(21):2660-8. doi: 10.1093/eurheartj/ehn408. [PubMed: 18826989].
  • 45. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, et al. Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47(7):1734-41. doi: 10.1161/STROKEAHA.116.013052. [PubMed: 27256671]. [PubMed Central: PMC4927222].
  • 46. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet. 2002;360(9350):2001-8. doi: 10.1016/S0140-6736(02)12001-0. [PubMed: 12504395].
  • 47. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135(11):939-53. doi: 10.7326/0003-4819-135-11-200112040-00005. [PubMed: 11730394].
  • 48. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: A systematic review and meta-analysis. BJOG. 2006;113(1):5-14. doi: 10.1111/j.1471-0528.2005.00797.x. [PubMed: 16398764].
  • 49. Arnson Y, Rozanski A, Gransar H, Otaki Y, Doris M, Wang F, et al. Hormone replacement therapy is associated with less coronary atherosclerosis and lower mortality. J Am Coll Cardiol. 2017;69(11):1408. doi: 10.1016/s0735-1097(17)34797-6.
  • 50. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933-41. doi: 10.7326/0003-4819-133-12-200012190-00008. [PubMed: 11119394].
  • 51. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 1993;153(1):73-9. doi: 10.1001/archinte.1993.00410010097008. [PubMed: 8422201].
  • 52. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 1998;352(9145):1965-9. doi: 10.1016/S0140-6736(98)05066-1. [PubMed: 9872245].
  • 53. Schaefer EJ, Genest JJ Jr, Ordovas JM, Salem DN, Wilson PW. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis. 1994;108 Suppl:S41-54. doi: 10.1016/0021-9150(94)90152-X. [PubMed: 7802728].
  • 54. Gofman JW, Delalla O, Glazier F, Freeman NK, Lindgren FT, Nichols AV, et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. J Clin Lipidol. 2007;1(2):104-41. doi: 10.1016/j.jacl.2007.03.001. [PubMed: 21291675].
  • 55. Jonas HA, Kronmal RA, Psaty BM, Manolio TA, Meilahn EN, Tell GS, et al. Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study. Ann Epidemiol. 1996;6(4):314-23. doi: 10.1016/S1047-2797(96)00048-8. [PubMed: 8876842].
  • 56. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52(2):124-31. doi: 10.1016/j.jacc.2008.04.009. [PubMed: 18598891]. [PubMed Central: PMC2958092].
  • 57. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845-52. doi: 10.1001/jama.283.14.1845. [PubMed: 10770146].
  • 58. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100(7):717-22. doi: 10.1161/01.CIR.100.7.717. [PubMed: 10449693].
  • 59. Akbari-Asbagh F, Mahmudan A. [Comparison of the effect of different HRT (estrogen alone and 2.5 and 5 mg medroxyprogesterone acetate) on blood lipids, fasting blood glucose, and glucose tolerance testing and postmenopausal women at Mirza Kuchak Khan Hospital, 82-81]. Tehran Uni Med J. 2005;63(9):742-50. Persian.
  • 60. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801-11. doi: 10.1056/NEJM199906103402306. [PubMed: 10362825].
  • 61. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The atherosclerosis risk in communities study investigators. N Engl J Med. 1993;328(15):1069-75. doi: 10.1056/NEJM199304153281501. [PubMed: 8384316].
  • 62. Aune B, Oian P, Omsjo I, Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol. 1995;173(6):1816-20. doi: 10.1016/0002-9378(95)90433-6. [PubMed: 8610768].
  • 63. Murphy DD, Cole NB, Greenberger V, Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci. 1998;18(7):2550-9. doi: 10.1523/JNEUROSCI.18-07-02550.1998. [PubMed: 9502814].
  • 64. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet. 2010;375(9709):132-40. doi: 10.1016/S0140-6736(09)61717-7. [PubMed: 20031199]. [PubMed Central: PMC3162187].
  • 65. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89(2):157-61. doi: 10.7326/0003-4819-89-2-157. [PubMed: 677576].
  • 66. Kardos A, Casadei B. Hormone replacement therapy and ischaemic heart disease among postmenopausal women. J Cardiovasc Risk. 1999;6(2):105-12. doi: 10.1177/204748739900600207. [PubMed: 10353070].
  • 67. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45. doi: 10.1056/NEJM198711123172001. [PubMed: 3313041].
  • 68. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335(14):1001-9. doi: 10.1056/NEJM199610033351401. [PubMed: 8801446].
  • 69. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137(4):273-84. doi: 10.7326/0003-4819-137-4-200208200-00012. [PubMed: 12186518].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments